ZR2 Sequential Immunochemotherapy for Newly Treated MCL
NCT05992597
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
Interventions
DRUG:
ZR2 RDHAP
Sponsor
Zhejiang Cancer Hospital